// App-Quantinova.ai

: A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.

Researchers

Presenter

  • Melvin Chua

Principal Investigators

  • Jure Murgic

  • Ali Hosni

  • Adriana Salcedo

  • Suzanne Kamel-Reid

  • Alejandro Berlin

  • Melania Pintile

  • Michael Fraser

  • Theodorus Van Der Kwast

  • Paul Christopher Boutros

  • Robert G. Bristow

Medical Centers

  • National Cancer Centre Singapore, Singapore, Singapore

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Universtiy Health Network, Toronto, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Manchester Cancer Research Centre, Toronto, ON, Canada

Locations

  • Singapore

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

  • Prostate specific antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved